Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological intervention of blood flow disturbances in diabetic retinal disease
2007-001697-84Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jun 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of latanoprost, diclofenac and dorzolamide in diabetic eye disease, diabetic retinopathy (DR) and diabetes mellitus type 1 (T1D), sponsored by Aarhus University Hospital. Primary endpoint: Change in retinal vessel diameters. Started Jun 2007; status: completed.
02
Drugs
latanoprostdiclofenacdorzolamide
03
Conditions
diabetic eye diseasediabetic retinopathy (DR)diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2007-001697-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001697-84.